Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

SUMMARY: Drug eluting stents (DES) were introduced in clinical practice to overcome the problem of in-stent restenosis (ISR) that limited the overall efficacy of percutaneous coronary revascularization with bare metal stent (BMS). Long-term outcome data confirm a sustained benefit of DES as compared with BMS. However, this benefit is mainly evident in the first year of follow-up. Indeed, DES-related events may extend over this time, due to late events (late ISR and/or very late stent thrombosis). Prevention of late failure of DES may become a specific therapeutic target.

Original publication

DOI

10.1016/j.carrev.2014.01.012

Type

Journal article

Journal

Cardiovasc Revasc Med

Publication Date

03/2014

Volume

15

Pages

100 - 108

Keywords

Drug-eluting stent, In-stent restenosis, Late events, Prevention, Stent thrombosis, Coronary Artery Disease, Coronary Restenosis, Coronary Thrombosis, Drug-Eluting Stents, Humans, Percutaneous Coronary Intervention, Prosthesis Design, Risk Factors, Time Factors, Treatment Outcome